
Omeros (OMER) Stock Forecast & Price Target
Omeros (OMER) Analyst Ratings
Bulls say
Omeros is well-positioned for future success with a stronger financial profile and recent operational progress, particularly in their YARTEMLEA and complement pipeline programs. The company has achieved key milestones, including a J-code assignment and successful launch of YARTEMLEA. Upcoming catalysts, such as a regulatory decision in 2026, continued launch execution and awareness, and a fully built U.S. field organization, could drive further growth and aid in the company's capital deployment plans.
Bears say
Omeros is facing several fundamental risks, including clinical and regulatory risk, partnership risk, financial risk, commercial risk, legal and intellectual property risk, and market share risk. Additionally, while the new J-code for its YARTEMLEA drug may improve visibility around reimbursement and use, there are still concerns about administrative delays and uptake in a rare, high-acuity setting. The company's financials also show a decline in royalty revenues, further adding to the negative outlook.
This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.
Omeros (OMER) Analyst Forecast & Price Prediction
Start investing in Omeros (OMER)
Order type
Buy in
Order amount
Est. shares
0 shares